Can the extent of heart rate reduction predict the clinical response of infantile haemangiomas to propranolol?

Br J Dermatol. 2018 Mar;178(3):e196-e197. doi: 10.1111/bjd.15966. Epub 2018 Jan 23.

Authors

J H Chong^{1

2}, S Prey², H T Mya³, A Delarue⁴, C Labreze²

Affiliations

¹ Department of Pediatric Medicine, Dermatology Service, KK Women's & Children's Hospital, 100 Bukit Timah Road, Singapore, 229899.
² Department of Pediatric Dermatology, National Centre for Rare Skin Disorders, Hôpital Pellegrin-Enfants, CHU de Bordeaux, Bordeaux, France.
³ Department of Hematology, Singapore General Hospital, Singapore.
⁴ Pierre Fabre Dermatologie, Lavaur, France.

PMID: 28886210
DOI: 10.1111/bjd.15966

No abstract available

Publication types

Letter

MeSH terms

Anti-Arrhythmia Agents / administration & dosage*
Bradycardia / drug therapy*
Bradycardia / physiopathology
Drug Administration Schedule
Female
Heart Rate / drug effects
Hemangioma / drug therapy*
Hemangioma / physiopathology
Humans
Infant
Male
Propranolol / administration & dosage*
Retrospective Studies
Treatment Outcome

Substances

Anti-Arrhythmia Agents
Propranolol